In preclinical studies, XMT-1522 demonstrated antitumor activity in trastuzumab emtansine-resistant HER2+ breast cancer and gastric cancer cell lines as well as trastuzumab emtansine-resistant PDX models (45). This evidence concerns the gene ERBB2 and gastric cancer.